12:00 AM
 | 
Nov 25, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Sitari Pharmaceuticals Corp., GlaxoSmithKline sales and marketing update

Avalon Ventures and GlaxoSmithKline launched celiac disease company Sitari, with $10 million in a series A round. The virtual newco, which is developing small molecule inhibitors of transglutaminase 2 ( TGM2; TG2), is the first to...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >